Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?
Open Access
- 13 July 2021
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 9 (7), 1505
- https://doi.org/10.3390/microorganisms9071505
Abstract
Beta-lactams are the most commonly prescribed antimicrobials in intensive care unit (ICU) settings and remain one of the safest antimicrobials prescribed. However, the misdiagnosis of beta-lactam-related adverse events may alter ICU patient management and impact clinical outcomes. To describe the clinical manifestations, risk factors and beta-lactam-induced neurological and renal adverse effects in the ICU setting, we performed a comprehensive literature review via an electronic search on PubMed up to April 2021 to provide updated clinical data. Beta-lactam neurotoxicity occurs in 10–15% of ICU patients and may be responsible for a large panel of clinical manifestations, ranging from confusion, encephalopathy and hallucinations to myoclonus, convulsions and non-convulsive status epilepticus. Renal impairment, underlying brain abnormalities and advanced age have been recognized as the main risk factors for neurotoxicity. In ICU patients, trough concentrations above 22 mg/L for cefepime, 64 mg/L for meropenem, 125 mg/L for flucloxacillin and 360 mg/L for piperacillin (used without tazobactam) are associated with neurotoxicity in 50% of patients. Even though renal complications (especially severe complications, such as acute interstitial nephritis, renal damage associated with drug induced hemolytic anemia and renal obstruction by crystallization) remain rare, there is compelling evidence of increased nephrotoxicity using well-known nephrotoxic drugs such as vancomycin combined with beta-lactams. Treatment mainly relies on the discontinuation of the offending drug but in the near future, antimicrobial optimal dosing regimens should be defined, not only based on pharmacokinetics/pharmacodynamic (PK/PD) targets associated with clinical and microbiological efficacy, but also on PK/toxicodynamic targets. The use of dosing software may help to achieve these goals.This publication has 83 references indexed in Scilit:
- Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathyCritical Care, 2013
- Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trialBMJ Open, 2012
- Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasisPediatric Nephrology, 2011
- Neurotoxic effects associated with antibiotic use: management considerationsBritish Journal of Clinical Pharmacology, 2011
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal FunctionAntimicrobial Agents and Chemotherapy, 2010
- Neurotoxicity induced by beta-lactam antibiotics: from bench to bedsideEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Drug-induced renal failure: a focus on tubulointerstitial diseaseClinica Chimica Acta; International Journal of Clinical Chemistry, 2005
- Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 childrenArchives of Disease in Childhood, 2004
- Factors predisposing to seizures in seriously III infected patients receiving antibiotics: Experience with imipenem/cilastatinThe American Journal of Medicine, 1988